MedTrace Logo

Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors

NCT05060432 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 153

Last updated 2024-06-21

No results posted yet for this study

Summary

This is a multicenter, open-label, phase I/II basket study, evaluating the safety, tolerability, RP2D, pharmacokinetics, pharmacodynamics and antitumor activity of EOS-448 (also known as GSK4428859A or belrestotug) combined with standard of care and/or with investigational therapies in participants with advanced solid tumors.

Conditions

Interventions

DRUG

EOS-448

Anti-TIGIT monoclonal antibody

DRUG

pembrolizumab

Anti-PD-1 monoclonal antibody

DRUG

inupadenant

A2A receptor antagonist

DRUG

Dostarlimab

Anti-PD-1 monoclonal antibody

DRUG

SOC chemotherapies

SOC chemotherapies in 1L mNSCLC

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • iTeos Therapeutics

    collaborator INDUSTRY

  • iTeos Belgium SA

    lead INDUSTRY

Principal Investigators

  • Iteos Clinical Trials · iTeos Belgium SA

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-06
Primary Completion
2024-07-31
Completion
2025-07-31
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • France
  • Italy
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05060432 on ClinicalTrials.gov